![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1533-0028&client=dukeuniv)
Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
Publication
, Journal Article
Hurwitz, HI; Honeycutt, W; Haley, S; Favaro, J
Published in: Clin Colorectal Cancer
May 2006
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor that has demonstrated increased overall survival when added to standard chemotherapy regimens for metastatic colorectal cancer. Herein we report the cases of 2 patients who demonstrated prolonged survival times of almost 5 and 6 years, respectively, on various chemotherapy regimens that also included bevacizumab. Throughout most of their disease course, these patients maintained a good quality of life, with some adjustments of chemotherapy doses because of side effects. Bevacizumab was generally well tolerated in long-term use.
Duke Scholars
Published In
Clin Colorectal Cancer
DOI
ISSN
1533-0028
Publication Date
May 2006
Volume
6
Issue
1
Start / End Page
66 / 69
Location
United States
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Humans
- Female
- Colorectal Neoplasms
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
Citation
APA
Chicago
ICMJE
MLA
NLM
Hurwitz, H. I., Honeycutt, W., Haley, S., & Favaro, J. (2006). Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clin Colorectal Cancer, 6(1), 66–69. https://doi.org/10.3816/CCC.2006.n.023
Hurwitz, Herbert I., Wanda Honeycutt, Sherri Haley, and Justin Favaro. “Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.” Clin Colorectal Cancer 6, no. 1 (May 2006): 66–69. https://doi.org/10.3816/CCC.2006.n.023.
Hurwitz HI, Honeycutt W, Haley S, Favaro J. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clin Colorectal Cancer. 2006 May;6(1):66–9.
Hurwitz, Herbert I., et al. “Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.” Clin Colorectal Cancer, vol. 6, no. 1, May 2006, pp. 66–69. Pubmed, doi:10.3816/CCC.2006.n.023.
Hurwitz HI, Honeycutt W, Haley S, Favaro J. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clin Colorectal Cancer. 2006 May;6(1):66–69.
![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1533-0028&client=dukeuniv)
Published In
Clin Colorectal Cancer
DOI
ISSN
1533-0028
Publication Date
May 2006
Volume
6
Issue
1
Start / End Page
66 / 69
Location
United States
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Humans
- Female
- Colorectal Neoplasms
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized